NCT00937703CompletedNot Applicable
Multicentric Evaluation of Two Telematics Systems (PDA Phone and IVS)in Type 2 Diabetics Patients in Failure of Oral Treatment and Having to Start a Treatment by Basal Insulin, Compared to a Conventional Care. National, Multicentric, Comparative Randomized Study
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète28 sites in 1 country180 target enrollmentStarted: December 1, 2008Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 180
- Locations
- 28
- Primary Endpoint
- Comparison HbA1c means of the 2 groups profiting from a telemonitoring system compared to the reference group.
Study Overview
Brief Summary
TELEDIAB-2 is a national, multicenter, controlled, randomised trial. The primary objective of the study is to show that during the initiation of a basal insulin treatment , a computerized decision-making system of adaptation of the insulin, coupled to a distance follow-up (thanks to PDAphone or an interactive vocal server (IVS)), is able to improve metabolic control at the end of 4 mouths as compared with conventional care.
Main judgment criteria: comparison of HbA1c means of the 2 groups profiting from a telemonitoring system compared to the reference group at 4 months.
Detailed Description
Secondary objectives :
- - To compare the 2 methods of telemonitoring employed.
- - To evaluate the speed of the glycemic attack of the objective to the rising, according to the method of follow-up employed.
- - To evaluate the satisfaction of the patients and the doctors with respect to systems of telemonitoring, and improvement of the quality of life (DQOL).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Supportive Care
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Type 2 diabetes since more than 3 years and claiming a strict balance glycemic;
- •Patients treated since at least 3 months, by metformin and secreting insulinic (KNOWN or glinide);
- •Patients uncontrolled with HbA1c ≥ 7.5% and < 10% at the inclusion.
- •BMI < 40 ;
- •Patients requiring a insulin treatment
- •Patients agree to start a slow insulin treatment
- •Patients already practising the glycemic self-monitoring or agree to learn it and practise it;
- •Patients able to include/understand operation and to use the PDA-phone and/or the SVI;
- •Patient not taking part in another biomedical research study
- •Patients agree to carry out at least 2 finger sticks per day;
- •More than 18 years, there is no higher age limit.
Exclusion Criteria
- •Patients introducing any evolutionary pathology associated and not stabilized, exhibitor with an uncontrolled diabetes during the year to come;
- •Patients in a situation which justifies of a clinical follow-up diabetologic more frequent than that (quarterly) envisaged by the study
- •Patients requiring a transitory passage to insulin;
- •Patients needing a hospitalization for the adaptation of insulin doses;
- •Patients presenting a cardiologic event
- •Patients presenting a hemoglobinopathy interfering with the proportioning of HbA1c;
- •Patients suffering from drug-addiction, alcoholism or psychological troubles
- •Type 1 or secondary diabetes
- •Patients who don't need strict metabolic objectives;
- •Pregnant or parturient patients
- •person with no freedom.
Arms & Interventions
Group1: Control group
Placebo Comparator
face to face visit à T4mounths
Intervention: placebo (Device)
Group2: IVS Group
Active Comparator
face to face visit at T4mounths plus telephone visits each 2 weeks
Intervention: IVS (Device)
Group3: PDAphone group
Active Comparator
PDA system face to face visit at T4mounths plus telephone visits each 2 weeks
Intervention: PDAphone (Device)
Outcomes
Primary Outcomes
Comparison HbA1c means of the 2 groups profiting from a telemonitoring system compared to the reference group.
Time Frame: To T4 months
Secondary Outcomes
- Comparison of evolution of HbA1c(T0 and T4 months)
- Comparison of the average jeun glycemia the 14 days previous the visit in 4 months(T4 months)
- Comparison of absolute HbA1c difference(T0-T4 months)
- Comparison of percentage of patients within the objective glycemic (the last 3 days Jeun Glycemia average with between 0.73 and 1.08 g/l) at the end of the study, and the average time allowing to achieve this goal(T0 and T4 months)
- Comparison of percentage of patients reaching HbA1c < 7.0% in 4 months(T0 and T4 months)
- Comparison of the evolution of the weight(T0 and T4 months)
- Comparison of evolution of the quality of life at the beginning and at the end of the study (the scale of quality of life DHP as well as the items of dimension Satisfaction of the DQOL)(T0 and T4 months)
- Effective number of patients carrying on the use of the system in routine care, at their own expense and in agreement with their physician(4 months)
- Comparison of the frequency of benign hypoglycemias, symptomatic or not, night and severe throughout study(study period)
- Comparison of the time spent by physicians with patients during visit (either face to face visits or phone call visit);(study period)
- Comparison of the satisfaction of the patients and physicians with the system and willingness to carry on the use of the system in routine care(4 months)
Investigators
Study Sites (28)
Loading locations...
Similar Trials
Completed
Phase 2
UTOLA: UTerin OLAparibEndometrial CarcinomaNCT03745950ARCAGY/ GINECO GROUP147
Completed
Phase 1
RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19COVID-19NCT04667247Gordon Saxe54
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT03161483Celgene289
Withdrawn
Phase 2
A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's DiseaseCrohn's DiseaseNCT01635621UCB BIOSCIENCES GmbH
Completed
Phase 2
SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)Sickle Cell DiseaseNCT03806452Theravia86